Head-to-head evidence
adalimumab-atto (Amjevita) vs etanercept
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline
adalimumab-atto (Amjevita)
Marketed by Amgen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07486843 (registry estimate)
etanercept · Enbrel
Marketed by Amgen
NCT00317499 · Phase 3 · completed
Participants were randomized to etanercept or placebo with quadruple-blinding. Substantially more patients on etanercept achieved a meaningful joint-symptom response than on placebo, a highly significant difference.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-atto (Amjevita)'s landscape · etanercept's landscape